Can You Take Azithromycin and Warfarin Together?

Azithromycin and warfarin can be taken together, but this combination requires careful monitoring because azithromycin may increase warfarin's anticoagulant effect, potentially elevating bleeding risk. While a direct pharmacokinetic interaction is not universally documented in FDA-approved labeling, clinical cases and postmarketing reports suggest that some patients experience elevated INR (International Normalized Ratio) when these drugs are combined, particularly with higher doses or prolonged azithromycin use. Any patient on warfarin who is prescribed azithromycin should inform their pharmacist and have their INR checked within 3–5 days of starting the antibiotic.

What the FDA Says

Neither the FDA-approved label for azithromycin nor warfarin explicitly lists the other as a contraindicated or formally documented interaction in the standard package insert. However, this absence of formal labeling does not mean the combination is without risk. The FDA Adverse Event Reporting System (FAERS) database contains sporadic reports of patients experiencing bleeding complications and INR elevation when azithromycin was added to warfarin therapy. Additionally, warfarin's prescribing information includes a broad warning that states: "Many drugs may increase the anticoagulant effect of warfarin, including… certain antibiotics."

Azithromycin is a macrolide antibiotic, a class that includes erythromycin and clarithromycin. Clarithromycin, for example, is listed in warfarin's prescribing information as a known inhibitor of warfarin metabolism. This precedent within the macrolide class has prompted clinicians and pharmacists to exercise caution when azithromycin is given to warfarin-treated patients, even though azithromycin itself is considered a weaker CYP3A4 inhibitor than clarithromycin.

How This Interaction Works

To understand why azithromycin and warfarin together may be problematic, we need to examine how warfarin is metabolized and how antibiotics can interfere with that process.

Warfarin is a prodrug that exists as a racemic mixture of S-warfarin and R-warfarin. S-warfarin is the more potent enantiomer and is metabolized primarily by the hepatic enzyme CYP2C9, with some contribution from CYP2C8 and CYP3A4. The anticoagulant effect of warfarin is achieved through inhibition of vitamin K-dependent clotting factors (II, VII, IX, and X), thereby reducing thrombin formation and prolonging the PT/INR.

Azithromycin is metabolized in the liver and is known to inhibit hepatic cytochrome P450 enzymes, particularly CYP3A4 and to a lesser extent CYP2C9. When azithromycin is given concurrently with warfarin, it may reduce the clearance of warfarin, leading to increased plasma concentrations and a prolonged anticoagulant effect. The clinical result is an elevated INR and increased bleeding risk.

The mechanism is not acute—it typically develops over 3–5 days after azithromycin is started—because azithromycin accumulates in tissues and CYP inhibition builds up gradually. Macrolides have a long tissue half-life and can persist in the body for days after the final dose, meaning the interaction may continue even after azithromycin is stopped.

It is important to note that not all macrolides carry equal risk. Azithromycin is generally considered to have weaker CYP3A4-inhibiting properties than clarithromycin or erythromycin, which is why the interaction with azithromycin is less predictable and less uniformly reported than with those alternatives. Individual variations in CYP2C9 genotype, hepatic function, and other medications can influence whether a clinically significant interaction occurs.

Who Is Most at Risk

Certain patient populations are at heightened risk if azithromycin and warfarin are combined without monitoring:

• Older adults (age ≥65) with reduced hepatic or renal function. Age-related declines in drug metabolism increase the likelihood of drug accumulation and interaction severity.
• Patients on high-dose warfarin (INR therapeutic range already at the upper limit) or those with narrow therapeutic ranges due to comorbidity.
• Patients with liver disease or impaired hepatic function, as the liver is the primary site of both warfarin and azithromycin metabolism.
• Patients taking multiple CYP3A4 or CYP2C9 inhibitors (e.g., fluconazole, verapamil, NSAIDs). A patient on warfarin plus azithromycin plus another P450 inhibitor faces compounded risk.
• Patients with renal impairment (eGFR <30 mL/min/1.73m²), as azithromycin may accumulate and prolong enzyme inhibition.
• Patients with active infections requiring prolonged antibiotic courses (>5 days of azithromycin), as the risk of interaction increases with duration of exposure.

Clinical Scenario 1: Atrial Fibrillation and Community-Acquired Pneumonia

A 68-year-old woman with paroxysmal atrial fibrillation has been stable on warfarin 5 mg daily for two years, with an INR consistently in the therapeutic range of 2.0–3.0. She presents to her primary care physician with a three-day history of productive cough, fever, and dyspnea. Chest X-ray shows left lower lobe infiltrates consistent with community-acquired pneumonia. The physician prescribes azithromycin 500 mg on day one, then 250 mg daily for four days—a standard five-day course.

The patient takes the first dose of azithromycin on a Monday. By Wednesday (day 3), she notices increased bruising on her shins and around her elbows, which she attributes to clumsiness. By Friday, she develops spontaneous gum bleeding and blood-tinged sputum. She calls her doctor, who orders an urgent INR, which comes back at 6.2—significantly elevated above her therapeutic range. She is advised to hold warfarin for one dose, reduce her daily dose to 3 mg, and recheck INR in two days. The interaction between azithromycin and warfarin had elevated her INR by nearly three points within five days of starting the antibiotic.

This scenario is realistic and has been documented in case reports in the medical literature. The key teaching point is that even when no formal interaction is listed in the package insert, clinical vigilance is essential.

Clinical Scenario 2: Urinary Tract Infection in a Warfarin-Treated Dialysis Patient

A 72-year-old man on hemodialysis for stage 5 chronic kidney disease is also on warfarin for a mechanical heart valve. His baseline INR is typically 2.5–3.5. He develops a symptomatic urinary tract infection with pyuria and dysuria. Urine culture is pending, so his nephrologist empirically prescribes azithromycin 500 mg daily for seven days (a longer course than typical, adjusted for renal impairment).

Four days into the azithromycin course, the patient develops hematuria and a nosebleed that does not stop easily. His wife insists he go to the emergency department. Laboratory testing reveals an INR of 7.1 and hemoglobin has dropped from 10.5 to 9.2 g/dL (suggesting bleeding). A detailed medication review reveals the concurrent use of azithromycin and warfarin. The patient is admitted, given fresh frozen plasma, and his warfarin is held for three days. He is switched to ceftriaxone (which has no significant interaction with warfarin) once the urine culture returns showing E. coli susceptible to beta-lactams.

This scenario highlights how renal impairment compounds the risk: azithromycin accumulation is greater in patients with reduced renal clearance, and dialysis does not efficiently remove macrolide antibiotics due to their large molecular size and tissue binding.

What to Do

For Patients:

• Always inform your pharmacist that you take warfarin before accepting any antibiotic prescription, including azithromycin.
• If azithromycin is deemed necessary by your doctor, ask when you should have your INR checked (typically within 3–5 days of starting the antibiotic, and again 2–3 days after stopping it).
• Do not stop taking warfarin on your own, and do not alter the dose without consulting your anticoagulation provider.
• Watch for signs of bleeding: unusual bruising, blood in urine or stool, nosebleeds, gum bleeding, or dark tarry stools. Call your doctor or go to the emergency department immediately if these occur.
• Keep a list of all your medications (including over-the-counter drugs and supplements) to share with your pharmacist and doctor.

For Healthcare Providers:

• When prescribing azithromycin to a warfarin-treated patient, consider safer alternatives first. For respiratory infections, amoxicillin-clavulanate or doxycycline have minimal interaction risk. For atypical coverage, consider respiratory fluoroquinolones (e.g., levofloxacin) if not contraindicated, or consult ID specialists.
• If azithromycin is necessary, order a baseline INR before starting the antibiotic, then repeat INR 3–5 days into therapy and again 3–5 days after the antibiotic is stopped.
• Counsel patients on bleeding precautions and clear instructions on when to seek emergency care.
• Be aware of patient-specific risk factors: age >65, liver disease, renal impairment, concomitant CYP inhibitors, and polypharmacy all increase interaction risk.
• Document the decision to use azithromycin despite warfarin use in the patient's chart, and communicate this decision to the patient's anticoagulation provider (if managed by a separate team).

When to Call Your Doctor or Pharmacist

Contact your healthcare provider immediately if you experience any of the following while taking azithromycin and warfarin together:

• Unusual or excessive bruising on the skin
• Bleeding from the gums, nose, or rectum
• Blood in urine (pink, red, or cola-colored urine)
• Vomit that looks like coffee grounds or contains blood
• Dark, tarry, or bloody stools
• Severe abdominal or back pain
• Severe headache or confusion
• Shortness of breath or chest pain

Even if symptoms are mild—such as small amounts of gum bleeding or a few new bruises—notify your pharmacist or doctor so that an INR check can be scheduled.

Key Takeaways

• While azithromycin and warfarin do not carry a universally documented interaction in FDA package inserts, the combination poses a real risk of elevated INR and bleeding, particularly with prolonged use or in vulnerable populations.
• Azithromycin is a weak CYP3A4 and CYP2C9 inhibitor; it may reduce warfarin clearance and increase anticoagulant effect. The interaction typically develops over 3–5 days and can persist for several days after azithromycin is stopped.
• Patients over 65, those with liver or kidney disease, and those on multiple P450 inhibitors face heightened risk. If the combination is necessary, INR monitoring within 3–5 days of starting azithromycin is essential.
• Safer antibiotic alternatives (e.g., amoxicillin-clavulanate, doxycycline, fluoroquinolones) should be considered first before prescribing azithromycin to a warfarin patient.
• All patients on warfarin should maintain an updated medication list and inform their pharmacist before filling any new prescription. Bleeding is a serious complication—seek emergency care if you notice signs of abnormal bleeding.

Sources

• FDA Drug Labeling via OpenFDA: open.fda.gov (search for warfarin and azithromycin package inserts)
• Warfarin (Coumadin) Prescribing Information. FDA-approved labeling.
• Azithromycin (Zithromax) Prescribing Information. FDA-approved labeling.
• NIH National Library of Medicine, DailyMed: dailymed.nlm.nih.gov (comprehensive drug labeling repository)
• FDA Adverse Event Reporting System (FAERS): fda.gov FAERS database
• Holbrook AM, Pereira JA, Labiris R, et al. Systematic review of warfarin and its interactions with drugs and foods. Arch Intern Med. 2005;165(10):1095–1106. PubMed PMID: 15911722.
• Stockley IH. Drug Interactions: A Sourcebook of Adverse Interactions, Their Mechanisms, Clinical Importance and Management. 11th ed. London: Pharmaceutical Press; 2016.
• Nutescu EA, Wittkowsky AK, Gibbs G. Overview of the management of patients on warfarin. Curr Med Res Opin. 2005;21(7):1109–1118. PubMed PMID: 16004680.

Drug interactions involving warfarin are complex and highly individual. While this post provides evidence-based information on the potential interaction between azithromycin and warfarin, no article can replace the expertise of your pharmacist or doctor. Before you fill any new prescription, verify your complete medication list—including over-the-counter drugs, supplements, and herbal products—using checkdruginteractions.com, our free, FDA-data-powered drug interaction checker. You can search your exact combination of medications in seconds and receive detailed, clinically referenced safety information. Your pharmacist will also use this data to help you make the safest choice.